View ValuationCellromax Science 将来の成長Future 基準チェック /06現在、 Cellromax Scienceの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Capital Markets 収益成長-1.8%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesNew Risk • May 31New major risk - Revenue and earnings growthRevenue has declined by 6.2% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 6.2% over the past year. Minor Risks Less than 3 years of financial data is available. Market cap is less than US$100m (₩52.2b market cap, or US$34.6m).お知らせ • Apr 21Cellromax Science Co., Ltd. (KOSDAQ:A471820) announces an Equity Buyback for KRW 1,000 million worth of its shares.Cellromax Science Co., Ltd. (KOSDAQ:A471820) announces a share repurchase program. Under the program, the company will repurchase up to KRW 1,000 worth of its shares pursuant to a contract with SHINYOUNG SECURITIES CO.,LTD. The purpose of the share repurchase is stock price stability and enhance in shareholder value. The repurchase program will expire on October 21, 2026. As of April 19, 2026, the company had 0 shares within scope available for dividend and had 103,532 shares in treasury through other repurchase.New Risk • Apr 03New major risk - Dividend sustainabilityThe dividend is not well covered by earnings and cash flows. Payout ratio: 0% Cash payout ratio: 93% Dividend yield: 3.8% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 0% Cash payout ratio: 93% Minor Risks Less than 3 years of financial data is available. Market cap is less than US$100m (₩54.8b market cap, or US$36.4m).お知らせ • Mar 17Cellromax Science Co., Ltd., Annual General Meeting, Mar 31, 2026Cellromax Science Co., Ltd., Annual General Meeting, Mar 31, 2026, at 10:00 Tokyo Standard Time. Location: auditorium, 357, guseong-ro, giheung-gu, gyeonggi-do, yongin South KoreaDeclared Dividend • Dec 18Dividend of ₩50.00 announcedShareholders will receive a dividend of ₩50.00. Ex-date: 29th December 2025 Payment date: 1st January 1970 Dividend yield will be 2.9%, which is lower than the industry average of 3.7%.New Risk • Dec 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (8.8% average weekly change). Market cap is less than US$100m (₩79.0b market cap, or US$54.0m).お知らせ • Sep 25Cellromax Science Co., Ltd. (KOSDAQ:A471820) agreed to acquire 17.17% stake in SNBioScience Inc. from OCI Holdings Company Ltd. (KOSE:A010060) for KRW 6 billion.Cellromax Science Co., Ltd. (KOSDAQ:A471820) agreed to acquire 17.17% stake in SNBioScience Inc. from OCI Holdings Company Ltd. (KOSE:A010060) for KRW 6 billion on September 23, 2025. A cash consideration of KRW 6 billion will be paid by Cellromax Science for 1.049609 million shares. The transaction will be financed through cash on hand available. The expected completion of the transaction is September 30, 2025.New Risk • Aug 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Market cap is less than US$100m (₩66.9b market cap, or US$47.7m).お知らせ • Jul 10Cellromax Science Co., Ltd. (KOSDAQ:A471820) announces an Equity Buyback for KRW 1,500 million worth of its shares.Cellromax Science Co., Ltd. (KOSDAQ:A471820) announces a share repurchase program. Under the program, the company will repurchase up to KRW 1,500 worth of its shares pursuant to a contract with SHINYOUNG SECURITIES CO.,LTD. The purpose of the share repurchase is stock price stability and enhance in shareholder value. The repurchase program will expire on January 9, 2026. As of July 8, 2025, the company had 184,000 shares within scope available for dividend and had 262,054 shares in treasury through other repurchase.お知らせ • Mar 14Cellromax Science Co., Ltd., Annual General Meeting, Mar 28, 2025Cellromax Science Co., Ltd., Annual General Meeting, Mar 28, 2025, at 10:00 Tokyo Standard Time. Location: auditorium, 357, guseong-ro, giheung-gu, gyeonggi-do, yongin South Korea このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Cellromax Science は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測KOSDAQ:A471820 - アナリストの将来予測と過去の財務データ ( )KRW Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/202620,9763,4182,6212,130N/A12/31/202522,1842,9662,2411,785N/A9/30/202523,2031,6196452,313N/A6/30/202523,3412,1132,2494,251N/A3/31/202522,3572,3512,3385,011N/A12/31/202421,6303,8173,5416,294N/Aアナリストによる今後の成長予測収入対貯蓄率: A471820の予測収益成長が 貯蓄率 ( 3.3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: A471820の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: A471820の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: A471820の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: A471820の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: A471820の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YDiversified-financials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/16 08:36終値2026/08/14 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cellromax Science Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • May 31New major risk - Revenue and earnings growthRevenue has declined by 6.2% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 6.2% over the past year. Minor Risks Less than 3 years of financial data is available. Market cap is less than US$100m (₩52.2b market cap, or US$34.6m).
お知らせ • Apr 21Cellromax Science Co., Ltd. (KOSDAQ:A471820) announces an Equity Buyback for KRW 1,000 million worth of its shares.Cellromax Science Co., Ltd. (KOSDAQ:A471820) announces a share repurchase program. Under the program, the company will repurchase up to KRW 1,000 worth of its shares pursuant to a contract with SHINYOUNG SECURITIES CO.,LTD. The purpose of the share repurchase is stock price stability and enhance in shareholder value. The repurchase program will expire on October 21, 2026. As of April 19, 2026, the company had 0 shares within scope available for dividend and had 103,532 shares in treasury through other repurchase.
New Risk • Apr 03New major risk - Dividend sustainabilityThe dividend is not well covered by earnings and cash flows. Payout ratio: 0% Cash payout ratio: 93% Dividend yield: 3.8% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 0% Cash payout ratio: 93% Minor Risks Less than 3 years of financial data is available. Market cap is less than US$100m (₩54.8b market cap, or US$36.4m).
お知らせ • Mar 17Cellromax Science Co., Ltd., Annual General Meeting, Mar 31, 2026Cellromax Science Co., Ltd., Annual General Meeting, Mar 31, 2026, at 10:00 Tokyo Standard Time. Location: auditorium, 357, guseong-ro, giheung-gu, gyeonggi-do, yongin South Korea
Declared Dividend • Dec 18Dividend of ₩50.00 announcedShareholders will receive a dividend of ₩50.00. Ex-date: 29th December 2025 Payment date: 1st January 1970 Dividend yield will be 2.9%, which is lower than the industry average of 3.7%.
New Risk • Dec 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (8.8% average weekly change). Market cap is less than US$100m (₩79.0b market cap, or US$54.0m).
お知らせ • Sep 25Cellromax Science Co., Ltd. (KOSDAQ:A471820) agreed to acquire 17.17% stake in SNBioScience Inc. from OCI Holdings Company Ltd. (KOSE:A010060) for KRW 6 billion.Cellromax Science Co., Ltd. (KOSDAQ:A471820) agreed to acquire 17.17% stake in SNBioScience Inc. from OCI Holdings Company Ltd. (KOSE:A010060) for KRW 6 billion on September 23, 2025. A cash consideration of KRW 6 billion will be paid by Cellromax Science for 1.049609 million shares. The transaction will be financed through cash on hand available. The expected completion of the transaction is September 30, 2025.
New Risk • Aug 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Market cap is less than US$100m (₩66.9b market cap, or US$47.7m).
お知らせ • Jul 10Cellromax Science Co., Ltd. (KOSDAQ:A471820) announces an Equity Buyback for KRW 1,500 million worth of its shares.Cellromax Science Co., Ltd. (KOSDAQ:A471820) announces a share repurchase program. Under the program, the company will repurchase up to KRW 1,500 worth of its shares pursuant to a contract with SHINYOUNG SECURITIES CO.,LTD. The purpose of the share repurchase is stock price stability and enhance in shareholder value. The repurchase program will expire on January 9, 2026. As of July 8, 2025, the company had 184,000 shares within scope available for dividend and had 262,054 shares in treasury through other repurchase.
お知らせ • Mar 14Cellromax Science Co., Ltd., Annual General Meeting, Mar 28, 2025Cellromax Science Co., Ltd., Annual General Meeting, Mar 28, 2025, at 10:00 Tokyo Standard Time. Location: auditorium, 357, guseong-ro, giheung-gu, gyeonggi-do, yongin South Korea